Ryan Kramer joined Ropes & Gray’s corporate department in 2022. Ryan primarily practices in the intellectual property transactions group, advising life sciences clients on a broad range of strategic transactions, including complex licensing arrangements, collaborations, mergers & acquisitions, and royalty monetization transactions.

During law school, Ryan served as a notes editor for the Boston University Law Review and as a lawyering fellow in the school’s first-year legal writing program. He also served as the networking director for the Health Law Association and worked as a research assistant focusing on consumer protection and privacy law.

Experience

  • Advised Novo Nordisk in an exclusive license agreement with The United Laboratories to develop, manufacture, and commercialize United’s UBT-251, a triple agonist of the receptors for GLP-1, GIP, and glucagon, for the treatment of diabetes, obesity, and other diseases globally, excluding Greater China, in a transaction worth up to $2 billion.
  • Represented Sarepta Therapeutics in a transformational global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple siRNA programs worth up to $11.35 billion.
  • Represented Novo Nordisk in a worldwide collaboration with Neomorph Inc. worth up to $1.46 billion to discover, develop and commercialize molecular glue degraders for multiple targets.
  • Advised ImmunoGen, Inc. on intellectual property matters related to its $10.1 billion sale to AbbVie Inc.
  • Represented Regeneron Pharmaceuticals in its acquisition of 2seventy Bio Inc.’s oncology and autoimmune programs as part of its newly launched R&D unit Regeneron Cell Medicines.
  • Represented the lead underwriters in the initial public offering of Loar Holdings Inc.
Expand all +